Bryan Oronsky

Company: EpicentRx

Job title: Chief Development Officer

Seminars:

RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases 11:30 am

Evaluate strategy and execution of drug design and translational development Understanding relevant pathology of disease and most up to date learnings on the inflammasome mechanisms, drug design, and patient population Exploring the latest data, potential biomarkers, challenges, and future directionsRead more

day: Day 1 - Track B - Morning